Why the study?
Does neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy improve disease-free survival in a child with hepatic angiosarcoma?
Does neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy improve disease-free survival in a child with hepatic angiosarcoma?
Total excision of the tumor combined with an aggressive chemotherapy regimen can lead to long-term disease-free survival in children with hepatic angiosarcoma.
Supports multimodal therapy feasibility in select pediatric hepatic angiosarcoma cases; hypothesis-generating and requires prospective validation.
We report a 3-year and 11-month-old Caucasian female, who initially presented with an unresectable hepatic angiosarcoma. After three courses of chemotherapy with adriamycin/cisplatin, the tumor decreased in size considerably, allowing complete surgical resection. She also received postoperative chemotherapy with alternating cycles of ifosfamide/etoposide, cisplatinum/adriamycin, and vincristine/actinomycin D/cyclophosphamide for 18 months. She remains disease-free for greater than 44 months from the initial diagnosis. Our experience suggests that total excision of the tumor, together with an aggressive chemotherapy regimen, can improve the disease-free survival for children with this highly malignant vascular tumor of the liver.
No takes yet. Share an insight, caveat, or question.
Gunawardena et al. (1997) studied this question.